Clinical Trials · NCT03035032

A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients

CompletedPhase 4Gonadorelin (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Astellas Pharma Singapore Pte. Ltd.
Enrollment
107
Start date
Jun 2017
Locations
19 sites, 8 countries
Primary endpoint
Number of Participants With Eligard Related Adverse Events (AE)
View Gonadorelin compound reference